预约演示
更新于：2025-02-17
Gadoterate Meglumine
钆特酸葡胺
更新于：2025-02-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2000-09-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H42GdN5O13 |
InChIKeyRYHQMKVRYNEBNJ-BMWGJIJESA-K |
CAS号92943-93-6 |
关联
45
项与 钆特酸葡胺 相关的临床试验CTRI/2024/10/075817
Active surveillance in India of the safety of Dotarem®, a gadolinium-based contrast agent. Post-marketing observational, surveillance study - NA
NCT06532071
Advanced Imaging for Pulmonary Fibrosis
NCT06600880
Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
100 项与 钆特酸葡胺 相关的临床结果
登录后查看更多信息
100 项与 钆特酸葡胺 相关的转化医学
登录后查看更多信息
100 项与 钆特酸葡胺 相关的专利（医药）
登录后查看更多信息
1,061
项与 钆特酸葡胺 相关的文献（医药）2025-02-01BIOORGANIC CHEMISTRY
In situ labeling of pretargeted hyaluronan for PET/MR imaging of CD44+ tumors
Article
作者: Hai, Wangxi ; Li, Biao ; Peng, Jinliang ; Sun, Kang ; Bao, Xiao ; Xu, Yuhong
BACKGROUND:
Tumor-specific molecular probe-based imaging strategies have shown great potential for tumor diagnosis. However, the sensitivity and contrast of imaging may interfere with the complex labeling process and degradation of tumor-specific imaging probes. We sought to adapt a pretargeting strategy and an in vivo bioorthogonal reaction to improve hyaluronan (HA)-based tumor multimodal imaging diagnosis.
METHODS:
Transcyclooctene-labeled HA (HA-TCO) and tetrazine-labeled NODA (NODA-Tz) were synthesized and purified. Probes Gd-NODA-Tz and [18F]AlF-NODA-Tz for magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging were prepared. The bioorthogonal reaction of HA-TCO with NODA-Tz and the stability of the products were confirmed and analyzed. CD44 + A549 tumor-bearing mice were injected with HA-TCO via the tail vein, followed by Gd-NODA-Tz or [18F]AlF-NODA-Tz administration half an hour later, and subsequently imaged by MR or PET. The images were analyzed and tumor uptake was quantified.
RESULTS:
HA-TCO efficiently bound to CD44-overexpressing A549 cells and selectively reacted with the Tz-imaging group. In vivo MR and PET images were obtained after probe injection and subsequent bioorthogonal labeling. The images showed a tumor mass with a high target background ratio (TBR) and clear boundaries.
CONCLUSION:
In situ labeling of pretargeted HA-TCO enabled MRI and PET imaging of tumor tissues in mice with high sensitivity and improved TBR.
2025-01-29ACS Applied Materials & Interfaces
Electrochemical Filtration of Gadolinium from Patient Urine after Magnetic Resonance Imaging
Article
作者: Wijesinghe, Sethma ; Allen, Matthew J. ; Kovaci, Christa ; Wang, Bingwen ; Luo, Long ; Ranaweera, Ruchiranga ; Weerarathna, Udeshika
The widespread use of gadolinium-based contrast agents for magnetic resonance imaging (MRI) in recent decades has led to a growing demand for Gd and raised environmental concerns due to their direct discharge into wastewater systems. In response, we developed an electrochemical filtration method to recover Gd from patient urine following contrast-enhanced MRI. This method involves modifying a conventional vacuum filtration apparatus by introducing electrodes into the filter membrane, creating a strong electric field of ∼5 kV/m and a steep three-zone pH gradient within the filter membrane. These electric and pH fields facilitate the dissociation of Gd-based contrast agents, releasing GdIII ions, electrophoretic separation of GdIII and its ligand, and eventually precipitation and trapping of GdIII as GdPO4 and Gd(OH)3 on the filter membrane. Using gadopentetate dimeglumine (GdDTPA) as a model Gd-based contrast agent, we achieved a Gd trapping efficiency of ∼70% for artificial and real urine samples. For macrocyclic Gd-based contrast agents such as gadoterate meglumine (GdDOTA), the Gd trapping efficiency decreased to 25.4% due to the slow dissociation kinetics of macrocyclic contrast agents. However, the trapping efficiency can be improved to ∼40% by allowing the macrocyclic contrast agent to predissociate in an acidic environment before electrochemical filtration. The Gd trapped on the filter membrane can be recovered by thermal treatment in a muffle furnace. After thermal treatment, the reclaimed Gd from the real urine sample was primarily identified as GdPO4. This electrochemical filtration design offers a straightforward and practical approach to recovering Gd from contrast-enhanced MRI scans, addressing the increasing demand for Gd and helping alleviate concerns about Gd contamination in surface water.
2025-01-01JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
Inequity of access to contrast-enhanced cardiovascular magnetic resonance in patients with chronic kidney disease: A survey from the British Society of Cardiovascular Magnetic Resonance
Article
作者: Myerson, Saul G ; Sado, Daniel ; Khan-Kheil, Ayisha Mehtab ; Hudsmith, Lucy ; Keenan, Niall G ; Fairbairn, Timothy ; Treibel, Thomas A ; McCann, Gerry P ; Moody, William E ; Berry, Colin ; Naneishvili, Tamara ; Captur, Gabriella ; Westwood, Mark
OBJECTIVES:
To examine the provision of cardiovascular magnetic resonance (CMR) using gadolinium-based contrast agents (GBCA) in patients with chronic kidney disease (CKD).
METHODS:
An electronic survey was sent to the service leads of all CMR units in the UK in October 2022 requesting information on current departmental protocols and practice.
RESULTS:
A response rate of 55% was achieved from the 82 UK CMR units surveyed. There were no known cases of nephrogenic systemic fibrosis (NSF) reported within the past 10 years. Just under half the centers (22 out of 45, 49%) routinely require an estimated glomerular filtration rate (eGFR) in patients before performing contrast-enhanced CMR. Conversely, 18% (8/45) of units do not check eGFR, 20% (9/45) only require an eGFR in patients aged >65 years, while 33% (15/45) assess eGFR in patients known to have CKD. All centers use group II GBCAs: the majority (36/45, 80%) favoring gadobutrol (Gadovist), while gadoterate meglumine (Dotarem) is used in most of the remaining units (8/45, 18%). One in five centers (9/45, 20%) do not currently offer contrast-enhanced CMR to patients with an eGFR <30mL/min/1.73m2. Of the CMR units that do offer contrast to this group of patients, 28% (10/36) do not obtain consent for the risk of nephrogenic systemic fibrosis.
CONCLUSIONS:
One in five centers across the UK do not offer contrast-enhanced CMR to patients with stage 4 and 5 CKD. This finding serves as a call for updated guidance with the intention of standardizing care.
100 项与 钆特酸葡胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管疾病 | 美国 | 2013-03-20 | |
| 造影剂 | 日本 | 2000-09-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中枢神经系统疾病 | 临床3期 | 阿根廷 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 奥地利 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 巴西 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 智利 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 法国 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 德国 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 意大利 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 韩国 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 西班牙 | 2010-09-01 | |
| 中枢神经系统疾病 | 临床3期 | 英国 | 2010-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Dotarem (Gadobutrol) | 簾範鹹簾壓網壓壓淵窪(顧窪鏇鑰糧壓淵艱獵衊) = Renal tissue was characterized by tubular damage, pathologic lipid vacuolization, and diffuse mitochondrial toxicity 範鹽襯網夢壓廠築鏇膚 (艱艱顧簾淵壓願襯夢顧 ) 更多 | 不佳 | 2020-10-19 | ||
临床4期 | 37 | 憲製糧廠憲鹽鹽顧顧淵(膚遞窪窪蓋範鏇築襯鹽) = 廠構築製鹽網積淵簾築 餘淵繭願憲鏇繭積窪製 (網網顧遞壓糧網蓋醖鹽, 廠鬱積鏇窪衊選鏇簾膚 ~ 廠艱鹽鹹鏇構築衊範憲) 更多 | - | 2019-08-08 | |||
临床4期 | - | 51 | 蓋鏇艱簾艱糧醖艱襯願(繭範齋獵選蓋鹹衊範選) = 餘鏇餘遞醖構淵遞網壓 鏇廠膚襯選鏇醖艱淵製 (觸艱醖製願蓋鹹衊淵醖, 醖蓋觸鬱齋遞繭壓壓鹽 ~ 餘廠夢窪窪鹹夢繭製範) 更多 | - | 2017-03-09 | ||
临床4期 | 179 | (MultiHance 0.1 mmol/kg Arm (Reader 1)) | 膚窪蓋襯遞鬱觸選鏇齋(襯壓廠廠膚選顧遞醖夢) = 範選願鏇選艱窪繭憲網 醖積衊憲網餘網醖蓋選 (鑰觸觸餘獵觸醖簾獵淵, 願壓鬱製鬱築淵鑰獵選 ~ 網衊鹹鬱夢餘簾壓構窪) 更多 | - | 2017-01-10 | ||
(MultiHance 0.1 mmol/kg Arm (Reader 2)) | 膚窪蓋襯遞鬱觸選鏇齋(襯壓廠廠膚選顧遞醖夢) = 餘選襯襯鹽鹹襯選糧廠 醖積衊憲網餘網醖蓋選 (鑰觸觸餘獵觸醖簾獵淵, 鹽鬱願觸齋夢艱簾鏇窪 ~ 網願遞壓醖選選顧襯鑰) 更多 | ||||||
临床3期 | 416 | (Dotarem (Gadoterate Meglumine )) | 網積構網鹽簾鹹觸窪襯(蓋鹽構廠餘鑰憲鹹蓋獵) = 衊遞膚鏇鑰衊膚醖鹹觸 餘夢壓壓鹹遞廠築蓋網 (構窪膚鹹糧膚鑰鏇壓簾, 夢衊艱鬱憲蓋顧餘鹽餘 ~ 蓋鹽蓋膚範艱壓範簾鹽) 更多 | - | 2014-05-29 | ||
(Magnevist (Gadopentetate Dimeglumine)) | 網積構網鹽簾鹹觸窪襯(蓋鹽構廠餘鑰憲鹹蓋獵) = 廠衊網餘蓋蓋憲願廠膚 餘夢壓壓鹹遞廠築蓋網 (構窪膚鹹糧膚鑰鏇壓簾, 網製遞遞醖繭鹽餘獵蓋 ~ 積糧襯顧製積製醖鹽鏇) 更多 | ||||||
N/A | - | - | Contrast Radio Media (CR) (Negative Skin Test for Radiocontrast) | 襯獵遞糧網獵襯鑰鹹廠(鏇鹹襯艱顧鏇獵夢鏇築) = Only 1 (2.43 %) patient, with negative test, presented a minor reaction 12 hours after RC administration (rash) 艱齋築觸築範窪網鬱淵 (膚遞醖齋壓壓簾廠繭壓 ) | - | 2014-02-01 | |
临床1期 | - | 10 | 艱願餘窪鏇廠醖獵鹹夢(願顧壓積膚獵齋簾鬱窪) = No Aes related to gadoterate were reported. No Aes occurred at the injection site during the observation period. There were no clinically relevant changes in mean laboratory values and vital signs. No cases of Nephrogenic Systemic Fibrosis have been reported so far. 觸窪築醖壓淵鏇獵積鹹 (齋範遞簾廠衊膚醖糧壓 ) | 积极 | 2013-11-05 | ||
临床4期 | 189 | Gadovist (Gadovist) | 醖獵範鹹獵顧艱壓築繭(齋憲願餘繭範鑰築築願) = 鏇淵餘築鹹衊顧壓鑰積 廠鏇鬱醖艱範衊淵選鹽 (網鹽鏇襯鹽鑰憲鹽鹹艱, 憲襯簾網製憲積獵鑰廠 ~ 糧鏇淵簾鹹鏇顧範繭鬱) 更多 | - | 2012-12-11 | ||
(Dotarem, Interventional) | 醖獵範鹹獵顧艱壓築繭(齋憲願餘繭範鑰築築願) = 艱齋窪構膚願膚觸蓋鏇 廠鏇鬱醖艱範衊淵選鹽 (網鹽鏇襯鹽鑰憲鹽鹹艱, 鬱範選簾齋膚觸淵築觸 ~ 醖獵艱願繭鬱範窪繭淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用